Want to see NTLA full AI Analyst Report?
NTLA Stock Chart & Stats
$13.51
-$0.37(-3.33%)
At close: 4:00 PM EDT
$13.51
-$0.37(-3.33%)
Day’s Range― - ―
52-Week Range$7.95 - $28.25
Previous CloseN/A
Volume3.46M
Average Volume (3M)5.17M
Market Cap
$1.60B
Enterprise Value$1.89B
Total Cash (Recent Filing)$437.76M
Total Debt (Recent Filing)$73.41M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Nov 05, 2026EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.36
Shares Outstanding140,126,700
10 Day Avg. Volume6,936,926
30 Day Avg. Volume5,166,792
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.45
Price to Sales (P/S)14.40
P/FCF Ratio-2.75
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue31.83
Enterprise Value/Gross Profit-68.48
Enterprise Value/Ebitda-4.85
Forecast
1Y Price Target
$19.91Price Target Upside47.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)-3.2
Revenue Forecast (FY)$50.26M
Bulls Say, Bears Say
Bulls Say
Lonvo-z Clinical Efficacy And Regulatory ProgressLonvo-z has demonstrated substantial Phase III efficacy in hereditary angioedema, including fewer attacks and freedom from therapy for many patients. FDA acceptance and Priority Review create a defined regulatory pathway, supporting potential commercialization and a durable leadership position in one-time gene-editing treatment.
Nex-z Biological ActivityNex-z has shown rapid, deep and sustained TTR reduction in early clinical testing, providing evidence that Intellia’s in vivo editing platform can produce meaningful biological effects. This broadens the company’s potential beyond HAE and supports continued value from its pipeline.
Cash Runway And Financial FlexibilityThe sizable cash position and expected runway into at least 2028 give Intellia time to complete late-stage development, pursue regulatory review and prepare commercialization without immediate dependence on product revenue. This flexibility is important for a capital-intensive clinical-stage biotech.
Bears Say
Persistent Cash Burn And Large LossesIntellia remains firmly in an investment phase, with substantial operating and free-cash-flow losses and no established product-sales base. Continued burn can consume financial resources before therapies generate revenue, increasing reliance on financing, partnerships or successful regulatory execution.
Nex-z Liver Safety SignalThe nex-z liver enzyme signal introduces a material development and regulatory risk for a major pipeline program. Although Intellia has added monitoring and mitigation, further safety findings could complicate trial execution, restrict eligible patients, delay approval or reduce the therapy’s commercial attractiveness.
Declining Collaboration RevenueThe decline in collaboration revenue highlights the variability of Intellia’s current funding model before commercial product sales. Lower partner-derived income can leave more development costs to the company, amplify cash burn and make future financial performance more dependent on milestones or successful launches.
Intellia Therapeutics News
NTLA FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was $7.95 and its highest was $28.25 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Intellia Therapeutics’s market cap is $1.60B.
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 18 days.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.799 by -$0.001.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics does not currently pay dividends.
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate is -0.8.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 140,126,700 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.799. Following the earnings report the stock price went up 2.461%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Currently, no hedge funds are holding shares in NTLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Intellia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.91 (47.37% Upside)
$19.91 (47.37% Upside)
Blogger Sentiment
Bullish
NTLA Sentiment 68%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 8.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $91.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.15%
12-Months-Change
Fundamentals
Return on Equity
-57.79%
Trailing 12-Months
Asset Growth
-4.64%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
NTLA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, concrete clinical progress — most notably the unequivocal Phase III success for lonvo‑z (87% attack reduction, 62% attack‑free and therapy‑free, favorable safety) and compelling nex‑z biological data (≈90% TTR knockdown, rapid and durable) — alongside active regulatory and commercial preparations. Financially, the company strengthened its cash position with a ~$195M financing and maintains a runway into at least 2028, although collaboration revenue declined and G&A rose as commercial build‑out continues. The primary concern is a nex‑z liver enzyme safety signal and the identification of an HLA C*05:01 subgroup (~12% of samples) associated with higher Grade 3+ transaminase events; the company has implemented mitigation, added HLA typing to protocols, and is engaging regulators. Overall, the positive clinical milestones and clear mitigation plan for the safety finding outweigh the operational and financial headwinds discussed.View all NTLA earnings summariesNTLA Revenue Breakdown
100.00% Collaboration revenue
NTLA Stock 12 Month Forecast
Average Price Target
$19.91
▲(47.37% Upside)
Technical Analysis
Kura Oncology
―
Compass Therapeutics
―
AbCellera Biologics
―
Janux Therapeutics Inc
―
Bicara Therapeutics Inc.
―
Ownership Overview
1.69% Insiders
15.31% Mutual Funds
0.57% Other Institutional Investors
52.91% Public Companies and Individual Investors